CMS publishes draft LCD for KidneyIntelX; coverage for type 2 diabetes and CKD stages 1-3b

Renalytix plc

CMS draft LCD covers KidneyIntelX and kidneyintelX.dkd for patients with type 2 diabetes and Stage 1–3b chronic kidney disease.
Medicare price set at $950 per test; distinct CPT codes on 2024 Clinical Lab Fee Schedule.
45-day public comment period opened Feb 8, 2024; ends March 23, 2024; final LCD expected in 2024.
Company formally requested the LCD from NGS and submitted peer-reviewed evidence; expert panel meeting held Aug 29, 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.